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Glucagon-like peptide 1 (GLP-1) is a hormone secreted predominantly by the distal small intestine and colon and released in
response to enteral nutrient exposure. GLP-1-based therapies are now used widely in the management of type 2 diabetes and
have the potential to be eﬀective antiobesity agents. Although widely known as an incretin hormone, there is a growing body of
evidence that GLP-1 also acts as an enterogastrone, with profound eﬀects on the gastrointestinal motor system. Moreover, the
eﬀects of GLP-1 on gastrointestinal motility appear to be pivotal to its eﬀect of reducing postprandial glycaemic excursions and
may, potentially, represent the dominant mechanism. This review summarizes current knowledge of the enterogastrone properties
of GLP-1, focusing on its eﬀects on gut motility at physiological and pharmacological concentrations, and the motor actions of
incretin-based therapies. While of potential importance, the inhibitory action of GLP-1 on gastric acid secretion is beyond the
scope of this paper.
1.Introduction
A role for gastrointestinal peptides (or factors) in the main-
tenance of mammalian glucose homeostasis had been spec-
ulated for more than 100 years. The search for these gut
peptides was stimulated initially by the discovery of secretin
by Bayliss and Starling in 1902 [1] and advanced by the
work of others [2–5]b e f o r ei tf e l lo u to ff a v o u r .I tw a s
revived subsequently by the observations, by Elrick et al.
[6]a n dM c I n t y r ee ta l .[ 7] in 1964, that an oral glucose
load resulted in a much greater insulin response than an
intravenous glucose load despite resulting in comparable
bloodglucoseconcentrations—theso-called“incretineﬀect”
[8]. Glucagon-like peptide-1 (GLP-1) was discovered in the
1980s following sequencing of the proglucagon gene and was
shown soon after that time to have fulﬁlled the physiological
criteria for an “incretin” as speciﬁed by Creutzfeldt [9],
that is, a hormone released from intestinal cells following
a nutrient load, which leads to a glucose dependent insulin
response. GLP-1 was the second incretin to be characterized
after glucose-dependent insulinotropic polypeptide (GIP),
which had been discovered a decade earlier.
GLP-1, however, does not ﬁt as well as GIP within
Creutzfeldt’s incretin deﬁnition [10]. For example, in healthy
subjects [11] and type 2 diabetic patients [12], postprandial
(as opposed to fasting) levels of insulin and C peptide
are decreased by exogenous GLP-1, rather than stimulated
(Figure 1), and when the slowing of gastric emptying
induced by GLP-1 is reversed by the prokinetic drug ery-
thromycin,theglucoseloweringeﬀectisattenuated[13].The
properties of GLP-1 as an enterogastrone (i.e., a factor that
slows gastric emptying and inhibits gastric acid secretion)
have also been appreciated [10, 14, 15]. In fact, it has been
suggested that the actions of GLP-1 to slow gastric emptying,
and thereby the entry of nutrients into the small intestine
to delay their absorption, may outweigh its insulinotropic
and glucagonostatic eﬀects [16]. In contrast to GLP-1, GIP
has little eﬀect on gastric emptying [17]. If anything, there
is some evidence that GIP may modestly accelerate emptying
from the stomach [18].2 Experimental Diabetes Research
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Figure 1: Blood glucose (a) and plasma insulin (b) concentrations during IV infusion of GLP-1, at 0.3 and 0.9pmol/kg/minutes, or 0.9%
saline, in 10 healthy humans. Data are means ± SEM. ∗GLP-1 0.3 and 0.9 versus saline: P<.05; #GLP-1 0.9 versus GLP-1 0.3: P<.05
(adapted from Little et al. 2006 [19], and used with permission from the publisher).
Some studies have reported reduced GLP-1 levels in type
2 diabetic patients [18, 20–24], although this has not been
found uniformly to be the case [25, 26]. It should be noted,
however, that the eﬃcacy of GLP-1-based therapy does not
depend on a deﬁciency of endogenous peptide. Pharmaco-
logical “replacement” of GLP-1 is not straightforward owing
to its very short half-life. GLP-1 is rapidly degraded by the
enzyme dipeptidyl peptidase-4 (DPP-4), making it imprac-
tical for most clinical applications. This has provided the
rationale for the development, and subsequent widespread
use, of synthetic longer-acting analogues, such as exenatide
and liraglutide (the two approved GLP-1 analogues), and
DPP-4inhibitors, like sitagliptin and vildagliptin, to improve
glycaemic control in type 2 diabetic patients [27].
2.The Physiology ofGastrointestinalMotility
An overview of the physiology of gastrointestinal motility is
useful in understanding the role and importance of GLP-1
in gut function. Gastric emptying, a highly regulated process
of delivering chyme from the stomach to the small intestine,
involves a complex interplay between the gastrointestinal
smooth muscle, gastric pacemaker cell networks, the so-
called interstitial cells of Cajal, and neurohormonal systems,
particularly inhibitory feedback arising from the interaction
of nutrients with the small intestine. Gastric and small in-
testinal motility is of predominutesantly two types: (a)
peristaltic, in the interdigestive or fasted phase, and (b) seg-
mented contractions in the fed, or postprandial state. Inter-
digestive motility is comprised of three sequential phases
(phase I or quiescent, lasting ∼40 minutesutes, phase II
or intermittent, lasting ∼50 minutesutes, and phase III or
regular contractions, at about 3/minutesute in the stomach
and 10–12/minutesute in the small intestine, and lasting ∼5–
10minutesutes)andiscalledthe“migratingmotorcomplex”
(MMC) [28]. Transit of indigestible solid occurs mainly in
late phase II and phase III of the MMC [29].
Once food (solid, liquid, or mixed) arrives in the stom-
ach, the MMC is replaced by the postprandial motor pattern.
For a solid or mixed meal, the proximal and distal parts of
the stomach have diﬀerent functions. The proximal stomach
is concerned with the storage of food and accommodates
the ingested meal by decreasing its tone [30, 31], enabling
its volume to increase without a substantial increase in
intragastric pressure [31, 32]. In contrast, the distal portion
of the stomach is concerned with the mixing and trituration
of the meal. Antral contractions pulverise the digestible
solid contents against the closed pylorus until they have
achievedasizeof1-2mm[33].Phasicandtoniccontractions
localised to the pylorus play a major role in the regulation
of gastric emptying so food particles are delivered to the
duodenum following the opening of the pylorus, predomin-
utesantly in a pulsatile manner [34] .T h er a t ea n dp a t t e r n
of gastric emptying are dependent on the composition
(solid, semisolid, or liquid), osmolarity, caloric content,
and size of the particles in the meal ingested. Liquids are
preferentially transferred to the small intestine before solids.
Nonnutrient liquids empty in an overall exponential pattern,
while a more linear rate is observed as the nutrient and
caloric content of the liquid meal increase. The presence of
food in the stomach reduces appetite, and distension of the
antrum, rather than the proximal stomach, appears to be
more strongly associated with the perception of postprandial
fullness [35], and suppression of subsequent energy intake
[36].
The exposure of the small intestine to nutrients triggers
a powerful inhibitory feedback to slow gastric emptying andExperimental Diabetes Research 3
small intestinal transit—the magnitude of this feedback is
dependent on the type of nutrient [37], as well as both
the length [38–40]a n dr e g i o n[ 40–42] of small intestine
exposed. GLP-1 and peptide YY (PYY), coexpressed with
GLP-1 in the entero-endocrine L cells predominutesantly
(but not exclusively) from the distal gut, appear to be potent
mediators of the so-called “ileal brake” [43]. This small
intestinal feedback mechanism results in highly regulated
gastric emptying of nutrients, including carbohydrate, from
the stomach to the small intestine at an overall rate of
about 1 to 4kcal/minutes [44, 45]. The release of GLP-1
from the small intestine is critically dependent on the car-
bohydrate load in both healthy subjects and type 2 diabetic
patients [45–48]. When glucose is infused intraduodenally
at the rate of 1kcal/minutes there is a minutesimal, and
transient, release of GLP-1, whereas there is a substantial,
and sustained, GLP-1 response to infusion at the rate of
4kcal/minutes[49], probably reﬂecting a greater length of
small intestinal exposure [38]. Fat (mediated by free fatty
acids),protein[50],andbileacids[51]arealsopotentstimuli
of GLP-1 release from the L cells. For carbohydrate, it has
been suggested that stimulation of intestinal “sweet taste”
receptors triggers GLP-1 release [52], although in humans,
the artiﬁcial sweetener, sucralose, does not induce GLP-1
secretion [53]. However, secretion of GLP-1 in response to
sucrose is increased when malabsorption is induced by the
α-glucosidase inhibitor, acarbose, presumably due to expo-
sure of the L cell—bearing distal gut to larger amounts of
carbohydrate [54].
The terminutesal aspect of the gastrointestinal tract, the
colon, is characterized by the presence of haustra (formed
bynonpropagatedphasiccontractions),whichcompartmen-
talise the luminutesal compartment and favour stool forma-
tion by water and electrolyte absorption. Colonic motility
is discontinuous, and mostly slow, which ensures prolonged
retention of contents, though occasionally rapid activity
allows large amounts of residue to be transferred across the
colon within seconds. Expulsion of contents is regulated by
the ano-rectum.
3. The Interrelationshipof GastricEmptying
withPostprandialGlycaemia
Postprandialhyperglycaemiaisbeingincreasinglyrecognised
as an independent predictor of cardiovascular mortality in
both diabetic and nondiabetic populations [55, 56]. The
rate of gastric emptying inﬂuences postprandial glycaemic
excursions and vice versa: a situation comparable to the
“chicken and egg” relationship [57]. Gastric emptying is a
major determinutesant of postprandial glycaemic excursions
in healthy subjects [45]a sw e l la st y p e1a n dt y p e2d i a b e t i c
patients [46] so that slower gastric emptying is associated
with reduction in blood glucose, especially in the ﬁrst hour
after ingestion of a meal [58, 59]( Figure 2). Conversely,
gastrointestinal motor function is highly sensitive to changes
in the glycaemic state [57]. For example, in both type 1 [60]
and type 2 diabetic patients [61], an increase in postprandial
blood glucose levels is associated with proportional slowing
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Figure 2: Relationship between the area under the plasma glucose
concentration curve between 0 and 30minutes and the retention of
the meal in the stomach at 30 minutes (r = 0.65, P<.01) (adapted
from Horowitz et al. 1993 [45] and used with the permission of the
publisher).
of gastric emptying. Even changes within the physiological
postprandial blood glucose range (i.e., 4mmol/L versus
8mmol/L) aﬀect gastric emptying in healthy as well as un-
complicated type 1 diabetic patients [62]. The slowing of
gastric emptying by acute hyperglycaemia reﬂects the stim-
ulation of pyloric motility [62, 63], suppression of antral
motility [64], and reduction in proximal gastric tone [65].
Acute hyperglycaemia also attenuates the ability of ery-
thromycin [66], and probably other prokinetic drugs, to
accelerategastricemptying.Incontrasttotheeﬀectofhyper-
glycaemia,insulin-inducedhypoglycaemiaacceleratesgastric
emptying substantially, probably representing a counter-
regulatory mechanism [67].
4.Effects on GastricMotility
It has been well established that GLP-1 slows gastric empty-
ing. The following section reviews the eﬀects of GLP-1 and
incretin-based therapies on gastric motility.
4.1. Exogenous GLP-1. Exogenous GLP-1 slows gastric emp-
tying in healthy [16, 19, 68], obese [69], type 2 diabetic [12],
andcriticallyillsubjects[70].InfusionofGLP-1slowsgastric
emptying of both solid and liquid components of a meal and
alters intragastric meal distribution so that a greater pro-
portion of the meal is retained in the distal stomach
[19]( Figure 3). Even at “low” doses (0.3pmol/kg/minutes,
designed to reﬂect “physiological” postprandial GLP-1
plasma concentrations) intravenous adminutesistration of
GLP-1 profoundly slows gastric emptying in a substantial
proportion of healthy subjects into the “gastroparetic” range
[19]. In both healthy subjects [16, 19, 71]a n dt y p e2
diabetic patients [12], the eﬀect of exogenous GLP-1 on
gastric emptying appears to be dose-related. Furthermore,4 Experimental Diabetes Research
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Figure 3: Gastric emptying curves for the solid and liquid components of a meal for the total, proximal, and distal stomach during IV
infusion of GLP-1 at 0.3 and 0.9pmol/kg/minutes, or 0.9% saline, in 10 healthy humans. Data are means ± SEM. ∗GLP-1 0.3 and 0.9 versus
saline: P<.05; #GLP-1 0.9 versus GLP-1 0.3: P<.05 (adapted from Little et al. 2006 [19] and used with permission from the publisher).
an inverse relationship between the early postprandial rise
in blood glucose and the rate of gastric emptying, following
infusion of exogenous GLP-1, indicates the importance of
the gastric motor actions of GLP-1 in its glucose-lowering
eﬀect [19]. As would be predicted by the slowing of gastric
emptying, exogenous GLP-1 relaxes the proximal stomach in
a dose-dependent manner [72], reduces antral and duodenal
motility, and increases pyloric tone in both the fasted and the
fed states [71].
4.2. Endogenous GLP-1. While a number of studies have
employed infusions of exogenous GLP-1 at “low” rates,
designed to reﬂect physiological postprandial GLP-1 concen-
trations, a more valid approach to assess the role of endoge-
nous GLP-1 is the use of a speciﬁc GLP-1 antagonist such
as exendin (9-39) amide. It appears that endogenous GLP-
1h a sam o d e s te ﬀect to slow gastric emptying and thereby
delay carbohydrate absorption, given a suﬃcient caloric
load [73], by mechanisms that include antral inhibition andExperimental Diabetes Research 5
stimulation of pyloric motility [34]. Three other studies
employing exendin (9-39) failed to show an eﬀect of endoge-
nous GLP-1 on gastric emptying [86–88] ,b u tt h i si sl i k e l y
to reﬂect methodological diﬀerences, including the use of
a suboptimal technique (plasma D-xylose) for measuring
gastric emptying in one study [87]. Furthermore, in one of
these studies [88] although no diﬀerence in gastric emptying
was observed, exendin 9-39 did change the intragastric
distribution of the meal, supporting the role of endogenous
GLP-1 in regulating gastric motility.
4.3. GLP-1-Based Therapies. The insulinotropic property of
GIP is markedly diminutesished in type 2 diabetic patients
[89–91], probably in part as an eﬀect of hyperglycaemia.
On the other hand, GLP-1 retains its properties (at supra-
physiological doses) in type 2 diabetic patients with potent
eﬀectsongastricmotilityandpostprandialglycaemiccontrol
[12]. Consequently, this hormone has been an important
target for the pharmaceutical industry in the treatment of
diabetes [12, 81, 92]. This has stimulated the development
of synthetic GLP-1 analogues, which are resistant to rapid
degradation, and inhibitors of the enzyme DPP-4 (which
boost concentrations of the active fraction of endogenous
GLP-1). Both classes of drugs are now used widely in the
management of type 2 diabetes.
4.3.1. GLP-1 Receptor Agonists. There are a number of GLP-
1 receptor agonists on the market or in development. Of
the established agents, exenatide and liraglutide, the former
has been best studied in regards to motor eﬀects. It appears
that an important mechanism contributing to the action of
exenatide, in reducing postprandial glycaemia, is by slowing
gastric emptying [81, 93]. Exenatide, derived from the saliva
of the Gila monster Heloderma suspectum, has been shown
to induce a dose-dependent deceleration of gastric emptying
in healthy subjects [80] and type 2 diabetic patients [82,
94]. Exenatide slows gastric emptying of both solid and
liquid components of a meal, irrespective of the presence
of established autonomic neuropathy [81]. However, in both
type 2 diabetic patients [81] and patients with critical illness
[70], the eﬀects of GLP-1 or incretin-based therapies appear
to be dependent on the prior rate of gastric emptying, so
that there is little further slowing in those with delayed
emptying at baseline. The relevance of this for selecting
the most appropriate patients to be treated with exenatide
and other GLP-1 agonists remains to be clariﬁed, but it is
clearly an important issue for further study. While animal
studies with long acting exenatide (LAR exenatide) have
failed to show evidence of tachyphylaxis (i.e., reduction in
pharmacological response over time) [95], a recent trial in
type 2 diabetic patients indicated that gastric emptying may
be more strongly slowed by twice daily exenatide than once
weekly LAR exenatide [96], suggesting that continuous GLP-
1 exposure could result in a diminutesution of pharmaco-
logical response, potentially reﬂecting changes in receptor
activation and/or changes in vagal function.
T h em a j o ra d v e r s ee ﬀects of exenatide and liraglutide are
nausea and vomiting. While these could relate to its eﬀects
ongastricmotorfunction,andantraldistensioninparticular
[35, 36, 97], the occurrence of adverse eﬀects seems not to
relate closely to the delay in gastric emptying [81, 96], and
it is possible that central mechanisms are important. The
eﬀects on gastric emptying have not been comprehensively
establishedforincretin-basedtherapiesotherthanexenatide,
but liraglutide also slows gastric emptying—the magnitude
of which is uncertain [83, 84]. Evaluation of this aspect of
drug action represents an important research priority for
these agents.
4.3.2. Dipeptidyl Peptidase-4 Inhibitors. Dipeptidyl pep-
tidase-4 inhibitors, including sitagliptin and vildagliptin,
result in an increase in circulating active GLP-1 concen-
trations [27, 98]b u ta p p e a rt oh a v e ,a tm o s t ,am o d e s t
eﬀect on gastric emptying [27]. Some deceleration in gastric
emptying was observed in a study of obese insulin resistant
monkeys treated with vildagliptin [85], but human studies
published to date have not demonstrated an eﬀect of DPP-
4 inhibitors on the rate of gastric emptying [82, 99, 100],
possibly because the elevation in active GLP-1 concentra-
tions is relatively modest. It should be noted that upper
gastrointestinal adverse eﬀects such as nausea and vomiting
are less commonly encountered with DPP-4 inhibitors than
with GLP-1 receptor agonists, and the relative lack of eﬀects
of the former on gastric emptying could well be relevant in
this regard.
5.Effects on SmallIntestinalMotility
The eﬀects of GLP-1 on small intestinal motility have not
been extensively studied. Exogenous, intravenous GLP-1
has been shown to inhibit murine fasted and fed small
bowel motility in a dose-dependent manner and appears
to have an additive eﬀect when combined with intravenous
GLP-2 in the fasted state [74]. Exendin (9-39) blocks the
inhibition of murine small intestinal motility induced by
intraduodenal infusion of peptone [75]. Suppression of
fasting small intestinal motility by exogenous GLP-1 is
also evident in healthy humans and those with irritable
bowel syndrome, manifested by a reduction in the frequency
of MMCs in a dose-dependent manner [76]. Indeed, the
GLP-1 analogue, ROSE-010, has been reported to be more
eﬀective than placebo at relieving abdominutesal pain in
irritable bowel syndrome patients [101]. None of the human
studies have hitherto evaluated the eﬀe c t so fG L P - 1o ri t s
analogues on postprandial small intestinal motility, but this
could represent an additional mode of glucose-lowering by
these agents, given that pharmacological inhibition of small
intestinal ﬂow events has been shown to reduce the rate of
smallintestinal glucoseabsorption in healthyhumans [102].
6. Effects on Colonic Motility
Only a handful of animal studies have speciﬁcally evaluated
the eﬀects of GLP-1 (exogenous or endogenous) on colonic
motility. Adminutesistration of intra-cerebroventricular
GLP-1 was reported to increase rat fecal pellet output and6 Experimental Diabetes Research
Table 1: Summary of motor eﬀects of GLP-1 and incretin-based therapies on the gastrointestinal tract.
Gastric motility
(delayed gastric emptying)
Small intestinal motility
(delayed small intestinal transit)
Large intestinal motility
(delayed colonic transit)
Endogenous GLP-1
(physiological dose) One positive study [73] No studies available No studies available
Exogenous GLP-1
(pharmacological dose)
Strong evidence in human
studies; healthy [16], obese [69],
type 2 diabetic [12], critically ill
[70]
Positive evidence in animal studies
[74, 75]. Positive eﬀect on fasting
motility in humans [76]
Positive evidence in animal
studies [77]. Only indirect
evidence in humans [78, 79].
GLP-1 receptor agonists
(e.g., exenatide, liraglutide)
Strong evidence with exenatide
(healthy) [80], (type 2 diabetes)
[80–82]. Some evidence with
liraglutide [83, 84]
No studies available No studies available
DPP-4 inhibitors
(e.g., sitagliptin, vildagliptin)
Positive evidence with animal
studies only [85] No studies available No studies available
this was reversed by the GLP-1 receptor antagonist, exendin
(9-39) [77]. Evidence for a role for GLP-1 in the regulation
of colonic transit in humans has been limited to the reports
of GLP-1 secreting tumors and their association with severe
constipation and markedly delayed colonic transit [78, 79].
7. Mechanismof Action of GLP-1and
Incretin-BasedTherapies on GutMotility
The mechanisms by which GLP-1, or incretin-based thera-
pies, exert their motor actions on the gut have not yet been
fully elucidated but appear to be complex. A number of
studies have indicated involvement of the vagal nerves in
mediating some of these eﬀects of GLP-1 [103–105]. Gastric
relaxation [68, 105] and postprandial gastric accommo-
dation [68], in response to exogenous GLP-1, are medi-
ated by vagal cholinergic pathways; antro-pyloro-duodenal
motility apparently is not [103]. Inhibition of fasting small
bowel motility in rats by exogenous GLP-1 is mediated via
endogenous nitric oxide (NO), while suppression of fed
motility is independent of NO [106]. Studies of the rodent
duodenum and colon suggest that GLP-1 can decrease exci-
tatory cholinergic neurotransmission in the enteric nervous
system via presynaptic GLP-1 receptors, which modulate NO
release [107].
Some gastrointestinal motor eﬀects of GLP-1 appear to
be centrally mediated—GLP-1 can readily diﬀuse through
the blood-brain barrier [77, 108] to gain access to GLP-1
receptors in the circumventricular organs, the subfornical
organ, and area postrema [109]; the latter in particular con-
trols vomiting. Albiglutide (or Albugon) is a newer GLP-1
receptor agonist that does not readily diﬀuse into the area
postremaandhasalowprevalenceofgastrointestinaladverse
eﬀects, possibly for this reason [110, 111].
8. Conclusion
ExploitingthepropertiesofGLP-1tothefullestfortherapeu-
ticpurposeswillrequireanin-depthunderstanding,notonly
of its incretin eﬀects but also of its impact on gut motility.
Although the last decade and a half has seen some important
steps in that direction, particularly in understanding the
impacts of GLP-1 and incretin-based therapies on gastric
e m p t y i n g ,i ti sc l e a r l yaw o r ki np r o g r e s s( Table 1). Further
research is needed to gain a better understanding of the
actions of GLP-1 and incretin-based therapies on small
bowel motility, the extent of the role of endogenous GLP-1
on gut function, and how strongly the motor eﬀects of
GLP-1-based therapies are maintained with long-term use.
The implications of eﬀects on gastric emptying and small
intestinal motility for glycaemic control in diabetes are
clinically signiﬁcant, as the former are often disordered in
long-standing diabetes.
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